NCT04099212 is a clinical trial in HYDRADENITIS, sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla.

Who is sponsoring NCT04099212?

NCT04099212 is sponsored by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla.

What condition does NCT04099212 study?

NCT04099212 studies HYDRADENITIS.

Is NCT04099212 still recruiting?

NCT04099212 is currently status unknown. Last updated 12 February 2020.

Last reviewed 2020-02-12 · How we verify

NCT04099212

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

15% TOPICAL RESORCINOL FOR HURLEY I-II HIDRADENITIS SUPPURATIVA.

Status unknown Last updated 12 February 2020

What this trial tests

trial in HYDRADENITIS in 40 participants. Status unknown.

Timeline

15 May 2019

Primary endpoint
30 April 2020

30 August 2020

Quick facts

Lead sponsor	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	40
Start date	15 May 2019
Primary completion	30 April 2020
Estimated completion	30 August 2020
Sites	1 location across Spain

Conditions studied

HYDRADENITIS — all drugs for HYDRADENITIS →

Sponsor

Fundación Pública Andaluza para la gestión de la Investigación en Sevilla — full company profile →

Who can join

18 and older, any sex, with HYDRADENITIS. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, observational cross-sectional study to evaluate the response of patients with HS I-II to monotherapy treatment of topical resorcin 15%, taking into account its safety, impact on quality of life and subclinical evolution.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Fundación Pública Andaluza para la gestión de la Investigación en Sevilla trials

Trials by the same sponsor.

NCT05225961 — ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem · Phase 4 · completed
NCT07521969 — Out-patiente Management for Gangrenous Acute Appendicitis: The PENDI-CSI II Randomized Clinical Trial. · NA · recruiting
NCT07153406 — Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients · Phase 3 · not yet recruiting
NCT07353424 — A Multicenter Randomized Clinical Trial Compared With Standard Clinical Practice to Evaluate the Efficacy of a Polypheno · NA · recruiting
NCT06602310 — Utility of Preanestes@s2.0, a Web Based Application for Preoperative Assessment. · NA · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04099212 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Last refreshed: 12 February 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04099212.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing